文献速递肿瘤 PET/CT神经核医学

18F-(2S,4R)-4-氟谷氨酰胺PET显像脑转移瘤患者

Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine.
PubMed 文献 · Clin Nucl Med · 2018-01-01

研究纳入14例疑似脑转移患者,先后行18F-FGln PET与18F-FDG PET,以功能与解剖影像综合结果为参照。18F-FGln PET病灶检出率81.6%,高于18F-FDG PET的36.8%;肿瘤/正常脑比值4.97±2.23 vs 1.22±0.69(P<0.05)。作者认为18F-FGln是脑转移有前景的新PET示踪剂,但肝、骨转移灶应用需更谨慎。

要点

  • 18F-FGln PET病灶检出率81.6%,18F-FDG PET为36.8%
  • 肿瘤/正常脑比值18F-FGln 4.97±2.23 vs 18F-FDG 1.22±0.69,P<0.05
  • 肝、骨转移灶因正常结构摄取,应用18F-FGln需更谨慎

核心结论

  • 18F-FGln初始显像显示其作为脑转移患者新型PET示踪剂具有前景。
  • 由于正常结构摄取,18F-FGln在肝和骨转移灶中的应用可能需要更谨慎。

研究设计与样本

  • 研究纳入7例男性和7例女性疑似脑转移患者,年龄25-67岁。
  • 3例患者行1小时动态全身PET/CT扫描,11例患者在注射后30±10分钟行静态全身扫描。
  • 所有患者在同一周内另行全身18F-FDG PET,并与增强MRI逐例比较。
  • 以所有功能与解剖影像的综合结果作为影像参照。

主要发现

  • 3例动态扫描显示注射后30±10分钟为识别脑转移的最佳时间点,对比度高。
  • 影像参照在6个解剖区域共显示38个病灶,所有患者脑转移均为阳性。
  • 18F-FGln PET与18F-FDG PET的病灶检出率分别为81.6%和36.8%。
  • 所有患者平均肿瘤/正常脑比值18F-FGln PET为4.97±2.23,18F-FDG PET为1.22±0.69,P<0.05。
  • 14个同时被两种显像显示的脑转移灶中SUVmax呈正相关(r=0.780,P<0.01);18F-FGln摄取似乎与肿瘤大小及周围水肿无关。

关键数值与推荐

  • 18F-FGln PET静态全身扫描时间为注射后30±10分钟。
  • 病灶检出率:18F-FGln PET 81.6% vs 18F-FDG PET 36.8%。
  • 肿瘤/正常脑比值:18F-FGln PET 4.97±2.23 vs 18F-FDG PET 1.22±0.69,P<0.05。
  • 14个双阳性病灶SUVmax相关r=0.780,P<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a need for an alternative PET probe, which does not show normal brain tissue uptake in the evaluation of metastasis to the brain. Therefore, we investigate the feasibility of F-labeled glutamine analog, F-(2S,4R)-4-fluoroglutamine (F-FGln), as a new metabolic probe to detect brain metastasis. METHODS: Patients (7 men and 7 women; age, 25-67 years) with suspected brain metastasis were enrolled for this study. All patients were imaged first with F-FGln PET (3 patients for 1-hour dynamic whole-body PET/CT scans, and 11 patients for static whole-body scans at 30 ± 10 minutes after injection), followed by a whole-body F-FDG PET performed in the same week. The characteristics of F-FGln PET imaging in brain metastasis patients were compared with that of F-FDG PET and/or contrast-enhanced MRI patient-by-patient. A composite of all functional and anatomic imaging studies served as the imaging comparator. RESULTS: Initial study in 3 patients using 1-hour dynamic scan showed that 30 ± 10 minutes after injection is optimal for identifying brain metastasis with a high-contrast ratio. All patients were positive for brain metastasis on this studies that demonstrated 38 lesions in 6 anatomic regions on the imaging comparator. The per-lesion detection rates for F-FGln PET and F-FDG PET were 81.6% and 36.8%, respectively. The average tumor-to-normal brain ratio of F-FGln PET was significantly better than that of F-FDG PET in all patients (4.97 ± 2.23 vs 1.22 ± 0.69, P < 0.05). Furthermore, our results suggest that F-FGln uptake in brain metastasis appeared to be independent of tumor size and peripheral edema. In addition, in 14 brain metastatic lesions visualized by both F-FDG PET and F-FGln PET imaging, a positive correlation of SUVmax was observed (r = 0.780, P < 0.01). As to the extracranial metastasis, both tracers showed a concordant increased radioactive uptake except in liver and bone. CONCLUSIONS: The initial imaging of F-FGln presenting a promising new PET radiotracer for patients with brain metastasis and its utility in the liver and bone metastatic lesions may require more caution due to uptake in normal structures.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xu X, Zhu H, Liu F, et al. Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine. Clin Nucl Med. 2018. PMID: 30179907. doi:10.1097/RLU.0000000000002257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。